Best Cell & Gene Therapy CDMOs in United States

· updated as new inspection, certificate, and trial data enters the platform

Cell & Gene Therapy manufacturers on CDMO Signal: 57 listed with manufacturing sites in the United States. 9 are fully evidenced (all four Signal Score pillars and at least one ClinicalTrials.gov match). The highest Signal Scores in that fully evidenced set are Bristol Myers Squibb (CGT Mfg) (in-house manufacturer, Signal Score 87), City of Hope (T Cell Manufacturing) (academic or national centre, Signal Score 84) and Takeda (also makes its own products, Signal Score 83.4). Outside that set, higher Signal Scores on this list include Pharmaron (Signal Score 86.9), FUJIFILM Diosynth Biotechnologies (Signal Score 86.7) and Charles River Laboratories (Signal Score 86.3). A higher score there is not a fully evidenced record. Signal Score is computed from FDA inspection records, EMA EudraGMDP and MHRA GMP certificates, and ClinicalTrials.gov. CDMOs cannot pay to change it. Updated 2026-11-20. Methodology.

Cell & Gene Therapy CDMOs in USA with the most regulatory evidence on file

Catalent
76.1
Tampa, FL
24 FDA inspections · 39 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-22 · VAI
Warning letter 2025-11-20
See the evidence →
FUJIFILM Diosynth Biotechnologies
86.7
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
0 FDA inspections · 35 EMA/MHRA GMP certs
Last FDA inspection: None on file
See the evidence →
AGC Biologics
79.9
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
4 FDA inspections · 27 EMA/MHRA GMP certs
Last FDA inspection: 2026-05-29 · NAI
See the evidence →
Thermo Fisher Scientific
77.6
Plainville, MA · Alachua, FL · Cambridge, MA
19 FDA inspections · 10 EMA/MHRA GMP certs
Last FDA inspection: 2026-06-30 · NAI
See the evidence →
Takeda
83.4
Boston, MA · Zurich, CH
4 FDA inspections · 20 EMA/MHRA GMP certs
Last FDA inspection: 2026-04-10 · NAI
See the evidence →
57
CDMOs tracked
55
Fully scored
22
With FDA records
111
FDA inspections
174
EMA/MHRA GMP certs
2
Warning letters

Cell and gene therapy manufacturing spans two adjacent product classes: living cell products (CAR-T, TCR, NK, stem cell therapies) and the viral vectors used to genetically modify them (AAV, lentiviral, adenoviral). The two are tightly coupled in ex vivo cell engineering — a lentiviral vector CDMO supplies the vector that a cell therapy CDMO uses to modify patient T cells for CAR-T. Sponsors running integrated programs benefit from CDMOs covering both, and the ranking below aggregates that combined view.

For platform-specific rankings, use the dedicated pages: <a href="/modality/cell-therapy">Cell Therapy CDMOs</a>, <a href="/modality/aav">AAV CDMOs</a>, <a href="/modality/lentiviral">Lentiviral Vector CDMOs</a>, <a href="/modality/adenoviral">Adenoviral Vector CDMOs</a>, <a href="/modality/gene-therapy">Gene Therapy CDMOs</a> (vectors only, no cell processing).

FDA inspection outcomes across these CDMOs: 48 NAI (no action), 61 VAI (voluntary action), 2 OAI (official action). Leading inspection & GMP sites: United States (93), Denmark (52), UNITED KINGDOM (37), Germany (23), UNITED STATES (14).

Last updated 2026-11-20. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.

Ranked by Signal Score (0–100). Fully evidenced marks a CDMO scored on all four pillars with at least one confirmed clinical program. Partly scored and profile-only CDMOs follow the scored rows. How we score

Showing contract manufacturers only.

# CDMO Signal Score Quality FDA · GMP Last FDA inspection Capacity Programs
1
PB
San Diego, CA · Shaoxing, China, Liverpool, UK, Ningbo China
86.9 100.0 5 insp · 1 GMP 2026-08-14 · NAI Available —
2
FD
Research Triangle, NC · Holly Springs, NC · Hillerod, DK
Hiring · 20 open roles
86.7 100.0 0 insp · 35 GMP None on file Expanding —
3
CR
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
86.3 99.2 9 insp · 11 GMP 2026-05-01 · NAI Limited —
4
KB
Durham, NC · Boulder, CO
Hiring · 97+ open roles
84.1 98.5 2 insp · 1 GMP 2026-04-01 · VAI Limited —
5
AJ
San Diego, CA · Osaka, JP
83.5 100.0 0 insp · 1 GMP None on file — —
6
TK
Boston, MA · Zurich, CH
Fully evidenced
Also makes its own products
83.4 100.0 4 insp · 20 GMP 2026-04-10 · NAI — 100 programs
7
MN
Philadelphia, PA · Allendale, NJ · Munich, DE · Yokohama, JP
83.1 99.2 3 insp · 4 GMP 2025-11-25 · NAI Limited —
8
MK
Darmstadt, DE · St. Louis, MO
Hiring · 8 open roles
Fully evidenced
Also makes its own products
81.9 98.8 2 insp · 2 GMP 2025-04-28 · VAI — 22 programs
9
LB
Incheon, KR · Syracuse, NY
Hiring · 8 open roles
81.6 100.0 2 insp · 0 GMP 2026-09-18 · NAI — —
10
EF
Planegg, DE · San Diego, CA
81.6 100.0 7 insp · 0 GMP 2026-05-15 · NAI — —
11
NW
Vilnius, LT; Waltham (MA), USA
Hiring · 16 open roles
80.8 100.0 0 insp · 8 GMP None on file Available —
12
BR
Glasgow, UK · Rockville, MD
Hiring · 16 open roles
Also makes its own products
80.3 97.2 6 insp · 10 GMP 2026-05-13 · VAI — —
13
AG
Longmont, CO · Milan, IT · Copenhagen, DK · Chiba, JP
Hiring · 38 open roles
Fully evidenced
79.9 99.8 4 insp · 27 GMP 2026-05-29 · NAI Available 2 programs
14
RC
Edinburgh, UK · Hopkinton, MA
Hiring · 8 open roles
79.3 96.8 1 insp · 1 GMP 2025-01-21 · VAI Available —
15
UM
Boston, MA
78.7 96.7 2 insp · 0 GMP 2025-12-18 · VAI — —
16
GZ
Indianapolis, IN · Lexington, MA
Hiring · 26 open roles
78.1 100.0 1 insp · 0 GMP 2025-08-27 · NAI Available —
17
AA
Rockville, MD · Alachua, FL · Munich, DE
78.1 100.0 0 insp · 1 GMP None on file — —
18
GP
San Diego, CA
78.1 100.0 0 insp · 1 GMP None on file — —
19
TF
Plainville, MA · Alachua, FL · Cambridge, MA
Hiring · 299 open roles
Fully evidenced
77.6 93.2 19 insp · 10 GMP 2026-06-30 · NAI Available 2 programs
20
AG2
San Carlos, CA
77.6 98.8 1 insp · 0 GMP 2025-04-18 · VAI — —
21
Tampa, FL
Hiring · 311 open roles
76.1 77.3 24 insp · 39 GMP 2026-05-22 · VAI
Warning letter 2025-11-20
— —
22
NR
San Diego, CA · Boston, MA · RTP, NC · Philadelphia, PA
Hiring · 100+ open roles
Fully evidenced
73.6 95.6 1 insp · 0 GMP 2025-01-21 · VAI Available 9 programs
23
EM
Baltimore, MD
Also makes its own products
66.1 — — None on file — 4 programs
24
VE
Rockville, MD · Memphis, TN · Keele, United Kingdom
64.0 — — None on file — —
25
PBI
Pennington, NJ · Nanjing, CN
64.0 — — None on file — —
26
AN
Columbus, OH
63.0 — — None on file Available —
27
AB
Research Triangle, NC · San Sebastian, ES
Also makes its own products
61.8 — — None on file — 10 programs
28
GF
Alameda, CA and South San Francisco
61.5 — — None on file Available —
29
FB
Columbus, OH
Hiring · 15 open roles
61.2 — — None on file Expanding 3 programs
30
MA
College Station, TX
59.0 — — None on file Available —
31
VB
Philadelphia, PA
59.0 — — None on file — —
32
MS
Princeton, NJ
59.0 — — None on file — —
33
WB
59.0 — — None on file — —
34
EB
Waltham, MA
Hiring · 8 open roles
59.0 — — None on file — —
35
AS
Lake Nona, FL
Hiring · 8 open roles
59.0 — — None on file — —
36
VM
Cambridge, MA
59.0 — — None on file — —
37
AP
Milpitas, CA
59.0 — — None on file — —
38
PO
San Diego, CA
Hiring · 3 open roles
Also makes its own products
58.7 — — None on file — 6 programs
39
KC
Gainesville, FL · Research Triangle Park, NC
Hiring · 8 open roles
56.5 — — None on file — —
40
UB
Shanghai, CN · Boston, MA
Hiring · 1 open role
56.5 — — None on file — —
—
Seal Beach, California, United States
Also makes its own products
Profiled — 3 insp · 0 GMP 2025-10-29 · VAI — —
—
San Diego, California, USA
Profiled — — None on file — —
How we score CDMOs →

What to evaluate in a Cell & Gene Therapy CDMO

Integrated vs point-solution CDMO
Ex vivo cell therapy programs benefit from CDMOs handling both vector and cell processing under one roof. Point-solution CDMOs specialize deeper but add tech-transfer complexity.
Regulatory record by process class
Cell therapy and viral vector inspections are separately scoped. Verify the CDMO's inspection record on the specific process class your program will use.
Chain-of-identity + cold chain
Autologous cell therapy demands per-patient scheduling, batch-of-one tracking, and cold-chain logistics that CDMOs vary meaningfully on. Confirm the CDMO's chain-of-identity software and cryopreservation posture.
Commercial track record
For late-stage programs, CDMOs with commercial-approved cell or gene therapy products on file carry demonstrable posture that ranking algorithms only partially capture.

FDA jurisdiction — how the ranking scores US-based CDMOs

The Signal Score's Quality Compliance pillar (35% of the composite) is dominated by FDA inspection data for US-based CDMOs: Establishment Inspection Report classifications (NAI, VAI, OAI), Form 483 observation counts, and Warning Letter history. For a CDMO whose primary facility footprint is US, this pillar carries direct weight — an inspection on the site slated for a sponsor's program applies without translation. For CDMOs with mixed US + international facility footprint, the ranking reflects the composite regulatory posture; sponsors evaluating for a specific program should verify inspection history on the exact US site under consideration via that CDMO's profile page.

Which US CDMOs also cover EU and UK regulatory geographies?

Many top-tier US-based CDMOs maintain EU (EMA) and UK (MHRA) GMP certification for facilities used to supply EU and UK trials or commercial markets. The Signal Score's Quality Compliance pillar includes EMA + MHRA certificate density as a component — a US-headquartered CDMO with dense EU/UK certificates typically ranks higher on this pillar than a US-only competitor. Sponsors running dual-jurisdiction programs should cross-check the individual CDMO profile pages for specific certificate coverage; the Europe region ranking surfaces CDMOs that also appear in the European jurisdiction ranking, indicating multi-region regulatory posture.

How CDMO Signal identifies US manufacturing presence

Region attribution is derived from each CDMO's declared facility locations in our directory. A CDMO's facility list is validated against corporate filings, press releases, and — where public — the FDA facility registration (FEI number lookups). Region matching is done at the country level: a US state name or two-letter abbreviation in the facility list places the CDMO in the US region. CDMOs with US + international sites appear in every applicable region ranking, which reflects operational reality — such a CDMO is a legitimate candidate for programs in any of those jurisdictions.

Cell & Gene Therapy CDMOs — Frequently Asked Questions

Who are the top Cell & Gene Therapy CDMOs?
Among Cell & Gene Therapy manufacturers with a fully evidenced Signal Score (all four pillars and at least one ClinicalTrials.gov match), the highest are Bristol Myers Squibb (CGT Mfg), City of Hope (T Cell Manufacturing), Takeda. The table above is the full list. CDMOs cannot pay to change a score.
How many Cell & Gene Therapy CDMOs have FDA inspection records?
CDMO Signal tracks 22 Cell & Gene Therapy CDMOs with FDA inspection records and 174 EMA/MHRA GMP certificates across the group.
What should I look for in a cell and gene therapy CDMO?
Start with process class match — cell therapy vs vector vs both. For ex vivo programs benefit from integrated CDMOs. Verify inspection record on the specific process class, confirm capacity match to your patient volume, and prioritize CDMOs with commercial-scale posture for late-stage work.
How many cell and gene therapy CDMOs does CDMO Signal track?
The table on this page is the live list: the union of cell therapy, AAV, lentiviral, adenoviral, and gene-therapy-tagged manufacturers. This is the broadest advanced-therapy candidate list on the platform. CDMOs cannot pay to change a score.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Save this Cell & Gene Therapy shortlist
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.
Related modalities
Cell Therapy CDMOs AAV / Gene Therapy CDMOs Lentiviral Vector CDMOs Gene Therapy CDMOs
Other Modalities
AAV CAR-T Lentiviral Cell Therapy mRNA/LNP Plasmid DNA Biologics Oligo/ASO Adenoviral Gene Editing Exosome Recombinant Proteins ADC Gene Therapy Viral Vector